COMT Activity and Hypnotizability

Trial ID: NCT04624880


Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to 40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use perioperatively, and may also be associated with hypnotizability or response to hypnotic analgesia. Analyzing COMT haplotypes from DNA extracted from saliva or blood using a giant magnetoresistive (GMR) nanotechnology platform may be faster, less expensive, and at least as accurate as pyrosequencing. This study aims to validate a multi-SNP point-of-care (POC) GMR assay for the rapid genotyping of SNPs predictive of COMT activity, and test the feasibility of using COMT activity as a biomarker for hypnotizability and/or response to hypnotic analgesia.

Official Title

COMT Activity as a Biomarker for Hypnotizability and Hypnotic Analgesia Using a Multiplexed Precision Medicine Platform

Stanford Investigator(s)

David Spiegel
David Spiegel

Jack, Lulu and Sam Willson Professor of Medicine

Jessie (Kittle) Markovits

Clinical Associate Professor, Medicine Clinical Associate Professor (By courtesy), Psychiatry and Behavioral Sciences


Inclusion Criteria:

   - Prior enrollment in one of 3 specific hypnosis trials

   - Enrollment is by invitation only

Exclusion Criteria:

   - Participants in the prior trials who declined to be contacted for future research.


device: Giant magnetoresistive sensor (GMR)

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jessie Kittle, MD